Outcome of large B-cell lymphoma patients treated with tafasitamab plus lenalidomide either before or after CAR-T-cells. - Université de Lille
Article Dans Une Revue Blood Advances Année : 2024

Outcome of large B-cell lymphoma patients treated with tafasitamab plus lenalidomide either before or after CAR-T-cells.

1 CLCC Henri Becquerel - Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen
2 Centre Hospitalier Universitaire [Rennes]
3 MOBIDIC - Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer
4 IPC - Institut Paoli-Calmettes
5 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
6 Université de Clermont-Ferrand
7 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
8 IC UM3 (UMR 8104 / U1016) - Institut Cochin
9 AP-HP - Hopital Saint-Louis [AP-HP]
10 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
11 Hôpital Henri Mondor
12 CHU Bordeaux - Centre Hospitalier Universitaire de Bordeaux
13 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
14 Inserm U354/Hôpital Saint-Antoine-APHP - Immunochimie des Régulations Cellulaires et des Interactions Virales
15 Service d'Hématologie biologique [CHU Limoges]
16 CHU Montpellier = Montpellier University Hospital
17 GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365
18 UNICAEN - Université de Caen Normandie
19 CHU de Poitiers [La Milétrie] - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
20 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
21 ICANS - Institut de Cancérologie de Strasbourg Europe
22 CHU Pitié-Salpêtrière [AP-HP]
23 Imagine - U1163 - Imagine - Institut des maladies génétiques (IHU)
24 CHU Angers - Centre Hospitalier Universitaire d'Angers
25 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
26 CHU Dijon
27 CHU Trousseau [Tours]
28 Département d'hématologie [Gustave Roussy]
29 CHU Amiens-Picardie
30 LYSARC - The Lymphoma Academic Research Organisation [Lyon]
31 ICSC - Institut Curie - Saint Cloud
J. Decroocq
  • Fonction : Auteur
O. Casasnovas
  • Fonction : Auteur
M. Joris
  • Fonction : Auteur

Résumé

Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre- or post-anti-CD19 CAR T-cell is currently debated. We analyzed large B-cell lymphoma patients in the DESCAR-T registry treated with axi-cel or tisa-cel in ≥3rd line (L3+) and TAFA-LEN before (n=15, 'TL-pre-CAR-T' set) or directly after (n=52, 'TL-post-CAR-T' set) CAR T-cell. We compared TAFA-LEN v. other treatments using inverse probability weighting in the TL-post-CAR-T set. In the TL-post-CAR-T' set, the median follow-up duration (mFUD) was 7 months, and the median progression-free survival, overall survival and duration of response since the 1st treatment for progression (mPFS2/mOS2/mDOR2) were 3, 4.7 and 8.1 months, respectively. The best overall response rate (bORR) and best complete response rate (bCRR) after TAFA-LEN were 13.5% and 7.7%, respectively. Outcomes were better for patients who relapsed >6 months after CAR T-cell (mPFS2: 5.6 vs. 2 months, p=0.0138; mOS2: not reached vs. 3.8 months, p=0.0034). bORR and bCRR between TAFA-LEN and other treatments were 20.6% vs. 24.9% and 11.6% vs. 15.6%, respectively. Outcomes were similar between TAFA-LEN and other treatments (mPFS2: 2.9 [2-2.6] vs. 2.4 [1.5-4.2] months, p=0.91; mOS2: 3.3 [1.8-6.4] vs. 5.5 [4.4-6.3] months, p=0.06). In an exploratory analysis of the TL-pre-CAR-T set (mFUD since CAR T-cell: 2.8 months), the median TAFA-LEN treatment duration prior to CAR-T was 3.7 months and no patients were reported to become CD19 negative. The bORR, bCRR, 6-month PFS and OS rates after CAR T-cell infusion were 45.5%, 36.4%, 20.1% and 58.2%, respectively. Neither TAFA-LEN nor comparative salvage treatments improved outcomes of patients who relapsed after CAR T-cell.

Domaines

Cancer
Fichier principal
Vignette du fichier
blooda_adv-2024-013726-main.pdf (1.62 Mo) Télécharger le fichier
blooda_adv-2024-013726-mmc1.pdf (1.93 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04708799 , version 1 (13-11-2024)

Licence

Identifiants

Citer

V. Camus, R. Houot, G. Brisou, B. Tessoulin, S. Bailly, et al.. Outcome of large B-cell lymphoma patients treated with tafasitamab plus lenalidomide either before or after CAR-T-cells.. Blood Advances, 2024, 8 (20), pp.5371-5381. ⟨10.1182/bloodadvances.2024013726⟩. ⟨hal-04708799⟩
48 Consultations
5 Téléchargements

Altmetric

Partager

More